HeiligHartziekenhuis Lier

The medical center is at the forefront of research in Persistent Spinal Pain Syndrome Type II (PSPS T2), focusing on innovative approaches to pain management. The center's research explores the efficacy of spinal cord stimulation (SCS) in conjunction with various pain medication tapering protocols.

• Spinal Cord Stimulation (SCS)
• Pain Medication Tapering Protocols
• Disability Assessment

By investigating different tapering strategies, the center aims to optimize patient outcomes and enhance the quality of life for those suffering from chronic spinal pain.

Specializing in the treatment of Ulcerative Colitis (UC), Inflammatory Bowel Disease Type Unclassified (IBDU), and Crohn's Disease (CD), the center is pioneering research on the use of subcutaneous infliximab following intravenous dose optimization. This research aims to improve clinical and biological outcomes for patients.

• Subcutaneous Infliximab Administration
• Intravenous Dose Optimization
• Clinical and Biological Remission

The center's work in this area seeks to refine treatment regimens, offering more convenient and effective options for patients with inflammatory bowel diseases.

Focusing on Localized ER+ Breast Cancer, the center is conducting groundbreaking research on the use of palbociclib as an alternative to traditional chemotherapy in older patients. This study evaluates the efficacy of combining endocrine therapy with palbociclib as an adjuvant treatment.

• Palbociclib as Chemotherapy Alternative
• Endocrine Therapy Integration
• Adjuvant Systemic Treatment

Through this research, the center aims to provide less invasive treatment options, reducing the burden of chemotherapy while maintaining efficacy in preventing cancer relapse.